2016
DOI: 10.1016/j.ijantimicag.2016.09.011
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 29 publications
0
4
0
Order By: Relevance
“…The authors of in vitro pharmacodynamic studies have described time-dependent killing for Staphylococcus epidermidis, 22,23 and the authors of an in vivo murine model reported no significant difference in the mortality rate in mice with a higher AUC 24 /MIC ratio. 24 Although there are population pharmacokinetic models that allow for the calculation of AUC with IIV dosing, 25 the use of CIV enables the AUC 24 to be easily calculated by using In contrast to studies in adults, 14 our study revealed that vancomycin-related adverse effects are extremely uncommon in young infants regardless of the method of administration. Importantly, infants in the CIV group required lower total daily doses of vancomycin compared with those in the IIV group.…”
Section: Discussionmentioning
confidence: 78%
“…The authors of in vitro pharmacodynamic studies have described time-dependent killing for Staphylococcus epidermidis, 22,23 and the authors of an in vivo murine model reported no significant difference in the mortality rate in mice with a higher AUC 24 /MIC ratio. 24 Although there are population pharmacokinetic models that allow for the calculation of AUC with IIV dosing, 25 the use of CIV enables the AUC 24 to be easily calculated by using In contrast to studies in adults, 14 our study revealed that vancomycin-related adverse effects are extremely uncommon in young infants regardless of the method of administration. Importantly, infants in the CIV group required lower total daily doses of vancomycin compared with those in the IIV group.…”
Section: Discussionmentioning
confidence: 78%
“…Ceftaroline (alone or in combination with rifampin) was clinically well tolerated by animals throughout the whole duration of treatment (no fur loss, no diarrhea or soft feces, and a 10% weight gain from baseline); these observations were already demonstrated by several authors in refractory MRSA infections such as bacteriemia or endocarditis where ceftaroline was well tolerated and effective ( 23 , 28 30 ).…”
Section: Discussionmentioning
confidence: 53%
“…Ceftaroline, a cephalosporin with potent activity against methicillin-resistant staphylococci approved by the US Food and Drug Administration (FDA) in 2010 and by the European Medicines Agency (EMA) in 2012, demonstrated high clinical success rates in treating MRSA osteomyelitis in some case reports and in the CAPTURE study experience ( 19 21 ). In addition to its in vitro activity against Staphylococcus epidermidis including MRSE strains, ceftaroline also recently demonstrated its safe and significant efficacy when used in monotherapy in a preclinical model of MRSE osteomyelitis and in an experimental model of foreign-body MRSE infection ( 22 , 23 ). However, little is known about the penetration of ceftaroline into the bone in the context of MRSE osteomyelitis and on its efficacy when used in combination with rifampin.…”
Section: Introductionmentioning
confidence: 99%
“…Several studies have evaluated the efficacy of ceftaroline against MRSA in experimental infection models, but few preclinical studies have evaluated its potential in MRSE models (23). In our MRSE osteitis model, ceftaroline alone showed a bacterial reduction of between 3 log 10 and 4 log 10 in the bone, with a complete sterilization obtained after 2 weeks of treatment.…”
Section: Discussionmentioning
confidence: 86%